AB0959 The activity of psoriatic arthritis with axial involvement correlates with PsAID12.
Authors: C. L. Iñíguez, G. Gonzalez Arribas, F. Maceiras-Pan, J. L. Guerra-Vazquez, V. Quevedo Vila, L. Fernández-Dominguez, C. García-Porrúa, J. A. Mosquera Martínez, J. A. Pinto Tasende
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with psoriatic arthritis (PsA) show an impact on the physical and psychological aspect of the disease and it can be measured with the PsA Impact of Disease (PsAID) questionnaire, and it is expected that the impact of the disease improves when the patient is in remission or low disease activity. Objectives To determine the rate of low impact of the disease in patients with PsA in daily clinical practice, and to evaluate its relationship with its axial activity. Methods A cross-sectional study was conducted in consecutive patients who met the CASPAR criteria, with positive clinical (DLI) and positive axial radiology, with or without peripheral involvement, and who were treated according to standard clinical practice (EULAR recommendations). Demographic, clinical, analytical data, HAQ index (0-3) and PsAID12 (0-10) were also collected. Patients were divided into 2 groups: those with a PsAID above 4 (high impact) or below 4 (low impact). Continuous variables are shown as median (Q1-Q3) and categorical variables as percentages and frequencies. The analyzes were performed using SPSS23 software. Differences were considered statistically significant if p &lt; 0.05. Results Of the 269 patients evaluated with PsA, 72 patients with axial involvement were included, 40 men (55.6%), with a median age of 54.1 years (45.0-62.0) and disease duration of 7 years (2-11). Obesity (BMI&gt;29.99) affected 28.3% and serum CRP level was 0.45 mgr/dl (0.08-1.10). The treatments of the patients were: NSAIDs 43.1%, corticosteroids 21.6%, csDMARD 52.9% and biological therapy 51.9%. The BASDAI was 4.2 (2.0-6.2) and the ASDAS-PCR was 2.4 (1.5-3.2), with 39.6% being in low activity or remission. The median PsAID total score was 3.9 (1.6-5.4), evaluated in 61 patients. The patients who achieved a PsAID12 ≤4 was 63% (see Table 1), more men and with a lower CRP. In addition, the low impact measured by the PsAID12 was associated with a lower BASDAI and ASDAS-PCR. PsAID≤4n=39 PsAID&gt;4n=22 p Age, years 54 (42-62) 54 (49-66) 0.284 Male gender, n % 28 (70) 10 (43.5) 0.038 Disease duration, years 7 (3-10) 5 (1.2-9.5) 0.432 CRP, mgr/dl 0.30 (0.04-0.79) 1.04 (0.07-2.44) 0.03 BSA, % 0.2 (0-1) 0.5 (0-1.5) 0.594 BASDAI 2.1 (0.8-4.0) 6.1 (4.4-6.9) &lt;0.001 ASDAS-PCR 1.5 (1.1-2-4) 3.1 (2.3-3.4) &lt;0.001 Conclusion Almost two thirds of patients with PsA with axial involvement in daily clinical practice had a low impact of the disease measured by PsAID12 and correlated with low activity in the BASDAI and ASDAS-PCR. References [1]Gossec L, et al. Annals of the Rheumatic Diseases 2014;73:1012-1019. Acknowledgements to Galician Rheumatology Society (SOGARE) Disclosure of Interests Carlota Laura Iñíguez: None declared, Guillermo Gonzalez Arribas: None declared, Francisco Maceiras-Pan Speakers bureau: Abbvie, Novartis, Janssen, Lilly, Jose L. Guerra-Vazquez: None declared, Víctor Quevedo Vila: None declared, Luis Fernández-Dominguez Paid instructor for: Janssen, Novartis, BMS, Carlos García-Porrúa Speakers bureau: Abbvie, Novartis, Janssen, Lilly, José Antonio Mosquera Martínez: None declared, Jose Antonio Pinto Tasende Speakers bureau: Abbvie, Novartis, Janssen, Lilly, Celgene, Consultant of: Janssen, Novartis